Overview of betrixaban and its role in clinical practice

@article{Lekura2018OverviewOB,
  title={Overview of betrixaban and its role in clinical practice},
  author={Jona Lekura and J. Kalus},
  journal={American Journal of Health-System Pharmacy},
  year={2018},
  volume={75},
  pages={1095–1102}
}
  • Jona Lekura, J. Kalus
  • Published 2018
  • Medicine
  • American Journal of Health-System Pharmacy
  • Purpose. The role of betrixaban in the prevention of venous thromboembolism (VTE) in acutely medically ill patients and its efficacy and safety profiles are reviewed. Summary. Acutely medically ill patients have a high risk of developing VTE during hospitalization, and this risk continues into the postdischarge phase. Extended‐duration betrixaban therapy has been evaluated in a large clinical trial (the APEX trial) and in a meta‐analysis of pooled data on acutely medically ill patients. These… CONTINUE READING
    3 Citations

    References

    SHOWING 1-10 OF 24 REFERENCES
    Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
    • 275
    • PDF
    Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    • 281
    • PDF
    Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    • 457
    • PDF
    Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility
    • 300
    • PDF
    A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    • 157
    • PDF
    Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients.
    • 88
    • PDF